Politics

Biotech CEO Reveals US Losing Clinical Trial Race to China Due to FDA Bottleneck

Tim Ferriss Show · #868: Tim’s Founder Kitchen — From Brainstorm to The President’s Office in Two Months (Featuring Jake Becraft, Strand Therapeutics) · June 2, 2026

Tim Ferriss Show

#868: Tim’s Founder Kitchen — From Brainstorm to The President’s Office in Two Months (Featuring Jake Becraft, Strand Therapeutics)

"The United States is actually in the process of very rapidly as a country falling behind China because what started as a place for American companies to come run clinical trials to get data and then take it to the FDA and then do larger trials in the United States has now created a flywheel structure within China where now just Chinese companies run their clinical trials faster than the American companies and then bring their Chinese-discovered drugs to the United States."

Jake Becraft, CEO of Strand Therapeutics, warned that China has built an industrialized clinical trial infrastructure so efficient that US companies are losing their competitive advantage. He explained that American biotech is being dragged overseas by burdensome FDA regulations, creating a capital flow to Chinese companies that can develop drugs faster and cheaper. This national security concern reached the White House, with the president including FDA reform in his legislative priorities just two months after Becraft's Washington Post op-ed.

About this episode

Tim Ferriss hosted Jake Becraft, CEO and co-founder of Strand Therapeutics, in an experimental two-part format tracking an actual policy influence campaign from initial brainstorming to presidential-level impact. The episode documented how a dinner conversation in Boston led to refined messaging, a Washington Post op-ed, congressional testimony, and ultimately the president's legislative priorities—all within two months. Becraft presented clinical data showing a stage 4 melanoma patient with widespread organ metastases achieving complete cancer clearance using Strand's programmable genetic medicine platform, remaining cancer-free 18 months later after exhausting all standard treatments. The conversation revealed that Strand has solved what Becraft called the "holy grail" of genetic medicine: intravenous delivery of genetic medicines to organs throughout the body, not just the liver. Becraft made the case that burdensome FDA regulations requiring $25 million and 18 months just to file paperwork for first-in-human trials are pushing American biotech companies to China, where industrialized clinical trial infrastructure enables faster, cheaper drug development. He proposed eliminating FDA pre-approval for Phase 1 trials, instead using a notification system like Australia's that relies on hospital review boards. The episode explored platform therapeutics as analogous to SpaceX's reusable rocket architecture—creating delivery systems that dramatically reduce time and cost for each successive "payload" or drug candidate. Becraft argued that biotech has become trapped in a real estate development mindset of single-asset exits rather than building generational companies, contrasting this with how Bezos built Amazon and Musk built SpaceX through patient capital and long-term vision. The conversation included detailed discussion of split-testing headlines, refining policy messaging for maximum impact, and the importance of storytelling that leads with solutions rather than problems. Becraft positioned the moment as biotechnology's potential "SpaceX moment" if policy reforms unlock rapid innovation before China dominates the biomedical industrial base.

Key takeaways

Becraft's op-ed on FDA reform reached the president's legislative priorities within two months of publication, an exceptionally fast policy turnaround.
Strand demonstrated complete cancer clearance in a stage 4 melanoma patient with widespread organ metastases who remained disease-free for 18 months.
FDA requires $25 million and 18 months just to file paperwork before first-in-human trials, compared to notification systems in Australia and China.
China has built industrialized clinical trial infrastructure causing American biotech companies to offshore drug development and threatening US competitiveness.
Strand's platform enables intravenous genetic medicines to reach organs throughout the body, solving the 30-year "holy grail" problem of delivery beyond the liver.
Becraft proposed eliminating FDA pre-approval for Phase 1 trials, shifting safety oversight to hospital review boards as in Australia's CTN system.
The biotech industry has become trapped in a real estate development model of single-asset exits rather than building platform companies like SpaceX or Amazon.